Dexamethason for the treatment of exacerbations in multiple sclerosis
Dexamethason for the treatment of exacerbations in multiple sclerosis
What it found
We found no results in the registry or in papers.
What was tested
Treatment tested
- Dexamethasone
Glucocorticoid receptor agonist
- Dexamethason
What it measured
Main measures
The number of patients who describe an improvement in their clinical status of at least 5 points on a 10 point Likert scale (0=unchanged, 9=complete recovery to the pre-exacerbation level) on day six.
Other measures (1)
1. The number of patients needing additional intravenous methylprednisolon-treatment. 2. The number of patients who describe an improvement of at least five points on a ten-point-Likert scale on day 14 and 28. 3. The number of patients with at least one point improvement on the Expanded Disability Status Scale (EDSS) on day six, 14, 28 compared to the EDSS-score at randomisation.
Disability progression
Who could take part
Relapsing and progressive · 18 and over
Show the full criteria
Inclusion criteria
Inclusion: 1) patients with multiple sclerosis (MS), diagnosed according to the MacDonald criteria with a relapsing-remitting or secundary progressieve subtype. Exclusion: 1) Use of corticosteroids in the previous three months
Exclusion criteria
Not separately supplied in the registry.
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
In this double-blind randomized controlled trial, we would like to show that treatment with a five day course of 16mg per day of oral dexamethason is effective for inducing recovery from an exacerbation in MS.
Loading reviews and guidelines…
Related trials
- A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group,
Phase 3 · Completed
Shown as good as the comparator
- Evaluating the Use of Prednisone to Decrease Pegylated Interferon Beta
Phase 4 · Status unknown
Paper found, not read
- Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects
Phase 4 · Stopped early
Stopped
- Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Bio
Phase 3 · Completed
Results posted, not judged
- ACTH in Progressive Forms of MS
Phase 2 · Stopped early
Stopped
- Safety, Pharmacokinetics and Pharmacodynamics Study With 2B3-201 in He
Phase 1 · Stopped early
Stopped
History
- Status changed from Ongoing to Status unknown
- Result signal changed from Ongoing to Status unknown
- Completion date changed from Not recorded to 1 September 2007
- Has posted results changed from Not recorded to false
Started
Jul 2006
Finished
Sept 2007